Tross Stuart A 4

4 · MANNKIND CORP · Filed Mar 25, 2026

AI-generated summary of this filing

Updated Mar 26, 2026

MannKind (MNKD) Chief People Officer Stuart A. Tross Receives RSU Awards

What Happened

Stuart A. Tross, MannKind’s Chief People & Workpl Officer, received two grants of restricted stock units (RSUs) on 2026-03-23: 221,000 RSUs and 217,000 RSUs, for a total of 438,000 RSUs. Both grants were reported as awards (transaction code A) with an acquisition price of $0 (derivative awards representing contingent rights to shares).

Key Details

Transaction date: 2026-03-23; Form 4 filed: 2026-03-25 (timely).
Grants: 221,000 RSUs and 217,000 RSUs; total 438,000 RSUs; acquisition price $0 (derivative).
Shares owned after transaction: not specified in the provided filing excerpt.
Footnotes of note:
- F1: Each RSU represents a contingent right to receive one share of MNKD common stock upon settlement.
- F2: One grant is performance-based and vests (if earned) on January 15, 2029 based on MannKind TSR vs. the Russell 3000 Pharmaceutical & Biotechnology Index; payout ranges from 0% to 300% of target depending on percentile ranking (interpolated).
- F3: The other grant follows time-based vesting: 25% on March 23, 2027, then 1/16th of the remainder quarterly thereafter.
Filing timeliness: filed within two business days of the transaction date (no late filing noted).

Context

These were awards, not open-market purchases or sales — no cash changed hands at grant. RSUs are derivative awards that convert to actual shares only if and when vesting conditions are met; their ultimate value depends on MNKD’s share price at settlement and, for the performance RSU, on relative TSR achievement.
For retail investors: awards signal company compensation actions and potential future dilution when/if RSUs vest and settle; they do not by themselves indicate insider buying or selling intent.

Form 4

Period: 2026-03-23

Chief People & Workpl Officer

Transactions

Award
Performance Restricted Stock Unit
[F1][F2]
2026-03-23+221,000→ 221,000 total
→ Common Stock, $0.01 Par Value (221,000 underlying)
Award
Employee Stock Option (right to buy)
[F3]
2026-03-23+217,000→ 217,000 total
Exercise: $2.44From: 2027-03-23Exp: 2036-03-23→ Common Stock, $0.01 Par Value (217,000 underlying)

Footnotes (3)

[F1]Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.
[F2]The performance-based restricted stock unit will vest on January 15, 2029. The number of shares delivered on the vesting date, as a percentage of the target specified [in Box 5 above], is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from April 1, 2026 until December 31, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the measurement period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.
[F3]25% vesting on March 23, 2027 and thereafter 1/16th quarterly.

Signature

/s/ Stuart A. Tross|2026-03-25

1 file